Tiziana Life Sciences (ADR) (TLSA)
Develops intranasal anti-CD3 immunotherapy for neuroinflammatory and neurodegenerative diseases.
$0.9990
Pre-market+0.06 (+6.48%)
At close$0.9382(−2.64%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions34 holders · as of Mar 31, 2026 | 4.92% | 3.13M ADS | |
| Otherremainder | 95.08% | 60.50M ADS |
63.63M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F, as of Mar 31, 2026
34 holders · 3.13M shares · 5 new positions · 10 increased · 9 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 2.17M | 3.40% | +405.4K | May 14, 2026 |
| Marshall Wace, LLP | 157.6K | 0.25% | −124.5K | May 15, 2026 |
| Zhang Financial LLC | 111.9K | 0.18% | +12.0K | May 6, 2026 |
| UBS Group AG | 95.7K | 0.15% | −9.5K | May 5, 2026 |
| Colony Group, LLC | 79.4K | 0.12% | −606 | May 15, 2026 |
| Geode Capital Management, LLC | 78.2K | 0.12% | 0 | May 15, 2026 |
| Goldman Sachs Group Inc | 75.7K | 0.12% | −34.6K | May 15, 2026 |
| HSBC Holdings PLC | 62.4K | 0.10% | 0 | Apr 30, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Laura Natalia Monica Fonda | 5.70% | 6.81M | 13G | Oct 28, 2025 ↗ |
| Chernett Jorey | 5.40% | 6.48M | 13G | Dec 10, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 12, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 15,000 | $1.11 | 44,772,230 |
| Jul 21, 2026 | Gabriele M. Cerronedirector, 10 percent owner: | Purchase | 42,357 | $0.9900 | 44,814,587 |
| Aug 4, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 83,807 | $0.9700 | 4,556,068 |
| Aug 5, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 237,616 | $1.00 | 4,793,684 |
| Aug 3, 2026 | Ivor Elrifiofficer: Chief Executive Officer | Purchase | 667,000 | $1.00 | 4,472,261 |
CongressHouse and Senate disclosures
Not reported.